- Report
- March 2024
- 175 Pages
Global
From €4802EUR$5,000USD£4,134GBP
- Report
- January 2024
- 144 Pages
Global
From €3745EUR$3,899USD£3,224GBP
- Report
- November 2023
- 149 Pages
Global
From €2400EUR$2,499USD£2,066GBP
- Report
- February 2024
- 150 Pages
Global
From €4562EUR$4,750USD£3,928GBP
- Report
- February 2023
- 100 Pages
Global
From €2641EUR$2,750USD£2,274GBP
Zinacef is a brand of cefuroxime, an antibiotic used to treat infections of the central nervous system (CNS). It is used to treat bacterial meningitis, brain abscesses, and other CNS infections caused by susceptible bacteria. It is also used to treat bacterial infections of the skin, urinary tract, and respiratory tract. Zinacef is available in both oral and injectable forms. The injectable form is used for more serious infections, while the oral form is used for milder infections.
Zinacef is a part of the larger market of CNS drugs, which includes antibiotics, anticonvulsants, antipsychotics, and other medications used to treat neurological disorders. These drugs are used to treat a wide range of conditions, including epilepsy, Alzheimer's disease, Parkinson's disease, and schizophrenia.
Companies in the Zinacef market include GlaxoSmithKline, Pfizer, Merck, and Sanofi. Show Less Read more